LOXIGEN, INC.

LoxiGen, Inc. is a Charleston, South Carolina drug development company focused on targeted therapies for hard-to-treat cancers including triple-negative breast cancer and kidney cancer, as well as fibrosis-driven diseases. Its next-generation lysyl oxidase (LOX) inhibitors break down the rigid tumor microenvironment to improve drug penetration and block key intracellular cancer processes. LoxiGen's candidates are best-in-class with excellent drug-like properties targeting drug-resistant solid tumors.